Brokerages predict that Kindred Biosciences Inc (NASDAQ:KIN) will announce earnings per share of ($0.33) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.29). Kindred Biosciences posted earnings of ($0.29) per share in the same quarter last year, which indicates a negative year over year growth rate of 13.8%. The firm is expected to issue its next earnings report after the market closes on Thursday, March 1st.
On average, analysts expect that Kindred Biosciences will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.24) to ($1.14). For the next year, analysts forecast that the company will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.37) to ($1.09). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Kindred Biosciences.
A number of equities analysts have recently issued reports on KIN shares. B. Riley restated a “buy” rating and set a $11.00 price objective on shares of Kindred Biosciences in a research report on Monday, November 20th. HC Wainwright started coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a “buy” rating and a $9.50 price objective for the company. Aegis restated a “buy” rating on shares of Kindred Biosciences in a research report on Friday, December 15th. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $9.63.
A number of institutional investors have recently made changes to their positions in the business. Virtu KCG Holdings LLC grew its stake in Kindred Biosciences by 41.7% in the second quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 4,495 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Kindred Biosciences by 18.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 42,100 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 6,600 shares during the period. Wells Fargo & Company MN grew its stake in Kindred Biosciences by 2.2% in the third quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after acquiring an additional 7,206 shares during the period. Prudential Financial Inc. grew its stake in Kindred Biosciences by 18.9% in the third quarter. Prudential Financial Inc. now owns 52,920 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 8,410 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Kindred Biosciences by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 83,543 shares of the biopharmaceutical company’s stock valued at $789,000 after acquiring an additional 8,995 shares during the period. 66.61% of the stock is owned by hedge funds and other institutional investors.
Shares of Kindred Biosciences (KIN) remained flat at $$8.55 on Friday. The stock had a trading volume of 54,000 shares, compared to its average volume of 70,748. Kindred Biosciences has a 12 month low of $5.00 and a 12 month high of $9.80.
TRADEMARK VIOLATION WARNING: This piece of content was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/03/14/zacks-brokerages-expect-kindred-biosciences-inc-kin-to-post-0-33-eps.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.